The Board of Regents of the University of Nebraska was awarded a $179,403 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to further develop and screen a series of flupirtine analogues as potential non-opioid analgesics for the treatment of chemotherapy-induced neuropathic pain (CINP). The specific aims of the 2-year funded project are to (1) strategically synthesize potent Kv7.2/7.3 activators with reduced hepatotoxicity, and (2) evaluate the analgesic efficacy of the flupirtine analogues in established mouse CINP models. This research builds upon the grantee's prior work demonstrating that one flupirtine analogue (Compound 5) exhibited faster metabolism and avoided the hepatotoxicity associated with the parent compound, while effectively ameliorating short-term CINP in preclinical studies. The project aims to develop novel non-opioid pain therapeutics that can relieve CINP and potentially treat other pain conditions and non-pain-related diseases.
Generated 2/25/25, 4:04 AM